Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1421-1437
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1421
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1421
Table 1 Comparison of baseline characteristics of cirrhosis patients with platelet counts < 20 × 109/L, 20-50 × 109/L and > 50 × 109/L
Characteristics | Total (n = 913) | Platelet count < 20 × 109/L (n = 23) | Platelet count 20-50 × 109/L (n = 168) | Platelet count > 50 × 109/L (n = 722) | P value |
Age (years) | 45 (35-54) | 42.0 (33-46) | 43 (34-53) | 45 (36-54) | 0.068 |
Sex (Males:Female) | 762 (83.5): 151 (16.5) | 20 (87.0): 3 (13.0) | 136 (81.0): 32 (19.0) | 606 (83.9): 116 (16.1) | 0.581 |
Heart rate (per minute) | 96 (86-110) | 94 (86-100) | 94 (85-110) | 96 (86-110) | 0.397 |
MAP (mm of Hg) | 82 (74-89) | 81 (74-84) | 81 (75-88) | 82 (73-89) | 0.771 |
Hemoglobin (g/dl) | 7.6 (6.1-9.4) | 8.3 (5.7-9.6) | 7.4 (6.0-8.7) | 7.8 (6.1-9.5) | 0.168 |
TLC (×109/L) | 6.5 (3.8-9.2) | 6.9 (3.7-9.6) | 5.1 (3.1-7.9) | 6.8 (4.2-9.7) | < 0.001b |
Platelet count (×109/L) | 96 (55-135) | 12.0 (10.0-15.0) | 40.0 (34.0-46.0) | 118.0 (80.0-150.0) | < 0.001b,c |
INR | 1.5 (1.3-1.9) | 1.7 (1.3-2.0) | 1.6 (1.3-1.9) | 1.5 (1.3-1.9) | 0.337 |
Serum urea (mg/dL) | 37 (24-64) | 45 (22-101) | 36 (23-55) | 37 (25-66) | 0.298 |
Creatinine (mg/dL) | 0.8 (0.6-1.2) | 1.1 (0.7-2.0) | 0.8 (0.6-1.1) | 0.8 (0.6-1.3) | 0.010a |
Sodium (meq/L) | 139 (135-142) | 137 (131-141) | 140 (136-143) | 139 (135-142) | 0.065 |
Bilirubin (mg/dL) | 1.6 (0.9-3.1) | 2.1 (1.0-7.7) | 1.7 (0.9-3.4) | 1.6 (0.9-2.9) | 0.317 |
AST (IU/L) | 51 (34-86) | 49.0 (35.0-103.0) | 56.0 (38.0-82.0) | 50.0 (33.0-87.0) | 0.410 |
ALT (IU/L) | 35 (23-55) | 36.0 (23.0-120.0) | 37.0 (24.0-56.0) | 34.0 (22.0-54.0) | 0.500 |
Albumin (g/dL) | 3.2 (2.7-3.8) | 2.8 (2.1-3.7) | 3.1 (2.7-3.8) | 3.2 (2.7-3.8) | 0.146 |
CTP | 7 (6-9) | 8.0 (7.0-10.0) | 7.0 (6.0-10.0) | 7.0 (6.0-9.0) | 0.044c |
MELD scores | 14.7 (11.1-20.3) | 17.2 (10.0-28.3) | 14.4 (11.3-19.6) | 14.8 (11.1-20.3) | 0.551 |
Ascites | 456 (49.9) | 12 (52.2) | 97 (57.7) | 347 (48.1) | 0.076 |
HCC | 35 (3.8) | 0 | 8 (4.8) | 27 (3.7) | 0.515 |
HE | 93 (10.2) | 2 (8.7%) | 22 (13.1) | 69 (9.6) | 0.382 |
Endotherapy | 0.815 | ||||
No therapy | 202 (22.1) | 7 (30.4) | 34 (20.2) | 161 (22.3) | |
Glue | 105 (11.5) | 1 (4.3) | 19 (11.2) | 85 (11.8) | |
Ethoxysclerol | 43 (4.7) | 2 (8.7) | 6 (3.6) | 35 (4.8) | |
EVL | 537 (58.8) | 12 (52.2) | 102 (60.7) | 423 (58.6) | |
APC | 2 (0.2) | 0 | 1 (0.6) | 1 (0.1) | |
Glue and EVL | 24 (2.6) | 1 (4.3) | 6 (3.6) | 17 (2.4) | |
Child Class | 0.047 | ||||
A | 374 (41.0) | 5 (21.7) | 65 (38.7) | 304 (42.1) | |
B | 361 (39.5) | 10 (43.5) | 61 (36.3) | 290 (40.2) | |
C | 178 (19.5) | 8 (34.8) | 42 (25.0) | 128 (17.7) | |
Etiology | 0.772 | ||||
Alcohol | 393 (43.0) | 9 (39.1) | 76 (45.2) | 308 (42.7) | |
Others | 520 (57.0) | 14 (60.9) | 92 (54.8) | 414 (57.3) | |
RBC | 0.548 | ||||
0 | 542 (59.4) | 12 (52.2) | 91 (54.2) | 439 (60.8) | |
1 | 143(15.7) | 4 (17.4) | 29 (17.3) | 110 (15.2) | |
≥2 | 228 (25.0) | 7 (30.4) | 48 (28.6) | 173 (24.0) | |
FFP transfusion | 108 (11.8) | 3 (13.0) | 23 (13.7) | 82 (11.4) | 0.689 |
Number of FFP transfusion | 3 (3-4) | 3 (3-3) | 3 (3-4) | 3 (3-4) | 0.728 |
Platelets transfusion | 91 (10.0) | 10 (43.5) | 53 (31.5) | 28 (3.9) | < 0.001a |
Number of platelet transfusion | 3 (3-3) | 3 (2.7-3.2) | 3 (3-3) | 3 (3-3.7) | 0.728 |
Rescue therapy (Radiological intervention) | 17 (1.9) | 2 (8.7) | 7 (4.2) | 8 (1.1) | 0.001a |
Grade of varices low:high | 128 (14.0): 785 (86.0) | 4 (17.4): 19 (82.6) | 24 (14.3): 144 (85.7) | 100 (13.9): 622 (86.1) | 0.885 |
Cause of bleed variceal | 0.898 | ||||
Esophageal | 789 (86.4) | 21 (91.3) | 148 (88.1) | 620 (85.9) | |
Fundal | 55 (6.0) | 1 (4.3) | 9 (5.4) | 45 (6.2) | |
Esophageal and Fundal | 69 (7.6) | 1 (4.3) | 11 (6.5) | 57 (7.9) |
Table 2 Rebleed rates at 5 days and 42 days, and mortality at 42 days in cirrhosis patients with platelet counts < 20 × 109/L, 20-50 × 109/L and > 50 × 109/L
Characteristics | Total (n = 913) | Platelet count < 20 × 109/L (n = 23) | Platelet count 20-50 × 109/L (n = 168) | Platelet count > 50 × 109/L (n = 722) | P value |
Rebleed at 5 d | 48 (5.3) | 3 (13.0) | 11 (6.5) | 34 (4.7) | 0.150 |
Rebleed at 42 d | 138 (15.1) | 5 (21.7) | 29 (17.3) | 104 (14.4) | 0.433 |
Death at 42 d | 166 (18.2) | 3 (13.0) | 39 (23.2) | 124 (17.2) | 0.153 |
Table 3 Comparison of baseline characteristics of cirrhosis patients who received platelet and those who did not
Before PSM analysis | After PSM analysis | |||||
Characteristics | Platelets transfusion (n = 91) | No platelets transfusion (n = 822) | P value | Platelet transfusion (n = 89) | No platelet transfusion (n = 89) | P value |
Age (yr) | 42 (34-50) | 45 (35-54) | 0.012 | 42 (34-50) | 40 (30-50) | 0.716 |
Sex (Male:Female) | 77 (84.6): 14 (15.4) | 685 (83.3): 137 (16.7) | 0.882 | 75 (84.3): 14 (15.7) | 80 (89.9): 9 (10.1) | 0.372 |
Heart rate (per minute) | 90 (84-100) | 96 (86-110) | 0.016 | 90 (85-100) | 89 (82-100) | 0.546 |
MAP (mm of Hg) | 81 (75-87) | 82 (74-90) | 0.341 | 81 (75-87) | 81 (73-88) | 0.968 |
Hemoglobin (g/dL) | 7.7 (6.1-9.4) | 7.6 (6.1-9.4) | 0.890 | 7.7 (6.1-9.4) | 7.5 (6.3-9.0) | 0.720 |
TLC (× 109/L) | 5.6 (3.1-8.3) | 6.6 (4.0-9.4) | 0.012 | 5.6 (3.1-8.3) | 7.0 (4.4-12.0) | 0.002 |
Platelet count (× 109/L) | 40.0 (32.0-58.0) | 100.0 (63.0-139.0) | < 0.001 | 40.0 (32.0-58.0) | 81 (57-126) | < 0.001 |
INR | 1.6 (1.3-2.0) | 1.5 (1.3-1.9) | 0.266 | 1.6 (1.3-2.0) | 1.7 (1.4-2.2) | 0.402 |
Serum urea (mg/dL) | 41 (28-60) | 36 (24-64) | 0.864 | 41 (28-61) | 34 (24-69) | 0.369 |
Creatinine (mg/dL) | 0.7 (0.5-1.0) | 0.8 (0.6-1.3) | 0.003 | 0.7 (0.5-1.0) | 0.8 (0.6-1.4) | 0.040 |
Sodium (meq/L) | 140.2 (137.0-143.0) | 139.0 (135.0-142.0) | 0.023 | 140 (137-143) | 140 (135-143) | 0.529 |
Bilirubin (mg/dL) | 1.7 (0.9-3.8) | 1.6 (0.9-3.0) | 0.771 | 1.7 (0.9-3.8) | 2.4 (1.3-4.8) | 0.071 |
AST (IU/L) | 49 (34-79) | 51 (34-88) | 0.570 | 49 (34-79) | 67 (38-119) | 0.019 |
ALT (IU/L) | 32 (22-58) | 35 (23-54) | 0.905 | 32 (22-58) | 41 (30-67) | 0.029 |
Albumin (g/dL) | 3.2 (2.7-3.8) | 3.2 (2.7-3.8) | 0.897 | 3.2 (2.7-3.8) | 3.1 (2.6-3.6) | 0.355 |
CTP | 7 (6-10) | 7 (6-9) | 0.119 | 8 (6-10) | 8 (6-10) | 0.186 |
MELD | 14.6 (10.9-20.2) | 14.7 (11.1-20.3) | 0.878 | 14.6 (10.9-20.2) | 16.1 (12.5-24.1) | 0.079 |
Ascites | 59 (64.8) | 397 (48.3) | 0.003 | 59 (66.3) | 58 (65.2) | 1.000 |
HCC | 6 (6.6) | 29 (3.5) | 0.150 | 6 (6.7) | 4 (4.5) | 0.747 |
HE | 15 (16.5) | 78 (9.5) | 0.044 | 15 (16.9) | 22 (24.7) | 0.268 |
Endotherapy (yes) | 71 (78.0) | 640 (77.9) | 1.000 | 72 (80.9) | 71 (79.8) | 1.000 |
Child class | 0.210 | 0.313 | ||||
A | 33 (36.3) | 341 (41.5) | 31 (34.8) | 22 (24.7) | ||
B | 34 (37.4) | 327 (39.8) | 34 (38.2) | 37 (41.6) | ||
C | 24 (26.4) | 154 (18.7) | 24 (27.0) | 30 (33.7) | ||
Etiology | 0.824 | 0.176 | ||||
Alcohol | 38 (41.8) | 355 (43.2) | 37 (41.6) | 47 (52.8) | ||
Other | 53 (58.2) | 467 (56.8) | 52 (58.4) | 42 (47.2) | ||
RBC | 0.483 | 0.294 | ||||
0 | 49 (53.8) | 493 (60.0) | 48 (53.9) | 56 (62.9) | ||
1 | 15 (16.5) | 128 (15.6) | 14 (15.7) | 15 (16.9) | ||
≥ 2 | 27 (29.7) | 201 (24.5) | 27 (30.3) | 18 (20.2) | ||
FFP transfusion | 22 (24.2) | 86 (10.5) | < 0.001 | 22 (24.7) | 22 (24.7) | 1.000 |
Grade of varices low:high | 71 (78.0) | 714 (86.9) | 0.026 | 69 (77.5) | 84 (94.4) | 0.002 |
Table 4 Cox-proportional analysis of variables associated with 42-days rebleeding in the whole cohort and after propensity score matching
Whole cohort | After propensity score matching | |||||||
Characteristics | Univariate analysis HR (95%CI) | P value | Univariate analysis HR (95%CI) | P value | Model 1 (Excluding CTP) | Model 2 (Including CTP) | ||
Adjusted HR (95%CI) | P value | Adjusted HR (95%CI) | P value | |||||
Age (yr) | 1.000 (0.987-1.013) | 0.973 | 1.007 (0.984-1.031) | 0.584 | ||||
Sex | ||||||||
Male | 1 | 1 | ||||||
Female | 0.662 (0.393-1.114) | 0.120 | 1.330 (0.560-3.158) | 0.517 | ||||
Heart rate (per minute) | 0.995 (0.986-1.004) | 0.298 | 1.011 (0.996-1.026) | 0.157 | ||||
MAP (mm of Hg) | 0.979 (0.965-0.992) | 0.002 | 0.966 (0.938-0.996) | 0.024 | 9.972 (0.938-1.008) | 0.131 | 0.968 (0.936-1.001) | 0.057 |
Hemoglobin (g/dL) | 0.969 (0.906-1.036) | 0.349 | 0.914 (0.800-1.045) | 0.189 | ||||
TLC (× 109/L) | 1.023 (0.995-1.053) | 0.111 | 0.991 (0.933-1.052) | 0.761 | ||||
Platelet count (× 109/L) | 0.999 (0.997-1.001) | 0.360 | 0.995 (0.989-1.001) | 0.129 | ||||
INR | 1.528 (1.296-1.802) | < 0.001 | 1.427 (0.976-2.086) | 0.067 | 1.341 (0.784-2.295) | 0.284 | ||
Serum urea (mg/dL) | 1.005 (1.001-1.008) | 0.012 | 1.004 (0.997-1.011) | 0.237 | ||||
Creatinine (mg/dL) | 1.158 (1.021-1.314) | 0.023 | 1.031 (0.805-1.319) | 0.811 | ||||
Sodium (meq/L) | 0.993 (0.966-1.022) | 0.647 | 0.980 (0.929-1.033) | 0.451 | ||||
Bilirubin (mg/dL) | 1.065 (1.045-1.086) | < 0.001 | 1.016 (0.976-1.058) | 0.434 | ||||
AST (IU/L) | 1.001 (1.000-1.001) | 0.005 | 1.001 (1.000-1.002) | 0.002 | 1.001 (1.000-1.002) | 0.284 | 1.001 (1.000-1.002) | 0.021 |
ALT (IU/L) | 1.000 (0.998-1.002) | 0.920 | 1.000 (0.998-1.003) | 0.761 | ||||
Albumin (g/dL) | 0.833 (0.672-1.031) | 0.093 | 0.543 (0.363-0.811) | 0.003 | 0.690 (0.431-1.105) | 0.122 | ||
CTP | 1.255 (1.177-1.337) | < 0.001 | 1.169 (1.048-1.303) | 0.005 | - | 1.081 (0.959-1.220) | 0.203 | |
MELD | 1.057 (1.038-1.077) | < 0.001 | 1.028 (0.995-1.063) | 0.102 | - | |||
Ascites, yes | 2.525 (1.757-3.630) | < 0.001 | 1.906 (0.939-3.870) | 0.074 | 0.857 (0.376-1.953) | 0.713 | ||
HCC, yes | 2.532 (1.367-4.690) | 0.003 | 0.370 (0.051-2.687) | 0.326 | ||||
HE, yes | 3.969 (2.700-5.836) | < 0.001 | 2.489 (1.324-4.679) | 0.005 | 1.791 (0.836-3.836) | 0.134 | ||
Endotherapy (yes) | 0.702 (0.480-1.027) | 0.069 | 0.999 (0.463-2.155) | 0.998 | ||||
Child class | ||||||||
A | 1 | 1 | ||||||
B | 1.849 (1.187-2.879) | 0.007 | 1.811 (0.738-4.444) | 0.195 | ||||
C | 4.653 (2.988-7.245) | < 0.001 | 3.695 (1.567-8.715) | 0.003 | ||||
Etiology | ||||||||
Alcohol | 1 | 0.095 | 1 | 0.124 | ||||
Other | 0.753 (0.539-1.051) | 0.622 (0.339-1.140) | ||||||
RBC (units) | ||||||||
0 | 1 | 1 | 1 | 1 | ||||
1 | 1.482 (0.944-2.327) | 0.087 | 1.162 (0.464-2.910) | 0.748 | 1.173 (0.460-2.992) | 0.738 | 1.253 (0.493-3.180) | 0.636 |
≥ 2 | 1.434 (0.979-2.098) | 0.064 | 2.571 (1.349-4.902) | 0.004 | 1.998 (0.962-4.152) | 0.064 | 1.900 (0.942-3.831) | 0.073 |
FFP transfusion | 3.078 (2.096-4.518) | < 0.001 | 1.490 (0.777-2.858) | 0.220 | ||||
Platelet transfusion | 2.613 (1.735-3.936) | < 0.001 | 2.204 (1.165-4.172) | 0.015 | 2.924 (1.448-5.903) | 0.003 | 2.702 (1.345-5.429) | 0.005 |
Grade of varices (high) | 0.829 (0.526-1.308) | 0.421 | 0.671 (0.311-1.446) | 0.308 |
Table 5 Cox-proportional analysis of variables associated with 42-days mortality in the whole cohort and after propensity score matching
Whole cohort | After propensity score matching | |||||
Characteristics | Univariate analysis HR (95%CI) | P value | Univariate analysis HR (95%CI) | P value | Adjusted HR (95%CI) | P value |
Age (yr) | 1.010 (0.998-1.022) | 0.118 | 1.016 (0.993-1.039) | 0.174 | ||
Sex | ||||||
Male | 1 | 1 | ||||
Female | 0.682 (0.427-1.088) | 0.108 | 0.889 (0.350-2.256) | 0.804 | ||
Heart rate (per minute) | 0.999 (0.990-1.007) | 0.759 | 1.004 (0.989-1.021) | 0.581 | ||
MAP (mm of Hg) | 0.988 (0.976-1.000) | 0.046 | 0.996 (0.967-1.027) | 0.816 | ||
Hemoglobin (g/dL) | 0.949 (0.892-1.010) | 0.100 | 0.992 (0.872-1.128) | 0.903 | ||
TLC (× 109/L) | 1.047 (1.023-1.071) | < 0.001 | 1.034 (0.986-1.084) | 0.172 | ||
Platelet count (× 109/L) | 0.998 (0.995-1.000) | 0.053 | 0.998 (0.992-1.003) | 0.422 | ||
INR | 1.903 (1.689-2.143) | < 0.001 | 1.656 (1.246-2.201) | 0.001 | 1.361 (0.825-2.244) | 0.228 |
Serum urea (mg/dL) | 1.009 (1.006-1.012) | < 0.001 | 1.005 (0.998-1.012) | 0.142 | ||
Creatinine (mg/dL) | 1.374 (1.263-1.495) | < 0.001 | 1.205 (1.004-1.446) | 0.046 | 0.985 (0.771-1.258) | 0.901 |
Sodium (meq/L) | 0.991 (0.966-1.017) | 0.494 | 0.996 (0.943-1.052) | 0.876 | ||
Bilirubin (mg/dL) | 1.077 (1.061-1.094) | < 0.001 | 1.040 (1.010-1.072) | 0.010 | 1.013 (0.967-1.061) | 0.588 |
AST (IU/L) | 1.001 (1.001-1.002) | < 0.001 | 1.001 (1.001-1.002) | < 0.001 | 1.001 (1.000-1.002) | 0.113 |
ALT (IU/L) | 1.002 (1.001-1.002) | < 0.001 | 1.001 (0.999-1.003) | 0.249 | ||
Albumin (g/dL) | 0.671 (0.548-0.821) | < 0.001 | 0.641 (0.433-0.948) | 0.026 | 0.964 (0.619-1.501) | 0.871 |
CTP | 1.369 (1.294-1.448) | < 0.001 | 1.239 (1.114-1.378) | < 0.001 | ||
MELD | 1.097 (1.080-1.115) | < 0.001 | 1.060 (1.029-1.091) | < 0.001 | ||
Ascites, yes | 2.673 (1.911-3.739) | < 0.001 | 1.876 (0.926-3.799) | 0.080 | 1.043 (0.431-2.525) | 0.925 |
HCC, yes | 1.637 (0.836-3.206) | 0.150 | 1.258 (0.390-4.063) | 0.701 | ||
HE, yes | 5.686 (4.102-7.881) | < 0.001 | 3.825 (2.014-6.953) | < 0.001 | 2.586 (1.260-5.307) | 0.010 |
Endotherapy, yes | 0.548 (0.394-0.760) | < 0.001 | 0.423 (0.226-0.790) | 0.007 | 0.589 (0.296-1.169) | 0.130 |
Child class | ||||||
A | 1 | 1 | ||||
B | 1.771 (1.142-2.747) | 0.011 | 1.002 (0.395-2.538) | 0.997 | ||
C | 6.785 (4.502-10.227) | < 0.001 | 3.759 (1.698-8.321) | 0.001 | ||
Etiology | ||||||
Alcohol | 1 | 1 | 1 | |||
Other | 0.641 (0.473-0.870) | 0.004 | 0.600 (0.329-1.094) | 0.096 | 0.920 (0.470-1.799) | 0.808 |
RBC | ||||||
0 | 1 | 1 | ||||
1 | 1 0.966 (0.629-1.484) | 0.874 | 1.158 (0.522-2.567) | 0.718 | ||
≥ 2 | 0.741 (0.505-1.086 | 0.125 | 1.024 (0.504-2.081) | 0.948 | ||
FFP transfusion | 2.532 (1.762-3.637) | < 0.001 | 1.923 (1.040-3.555) | 0.037 | 1.066 (0.510-2.230) | 0.865 |
Platelet transfusion | 1.489 (0.958-2.312) | 0.077 | 1.098 (0.608-1.984) | 0.757 | ||
Grade of varices (high) | 1.348 (0.826-2.198) | 0.232 | 0.880 (0.392-1.975) | 0.757 |
- Citation: Biswas S, Vaishnav M, Pathak P, Gunjan D, Mahapatra SJ, Kedia S, Rout G, Thakur B, Nayak B, Kumar R, Shalimar. Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding in patients with chronic liver disease. World J Hepatol 2022; 14(7): 1421-1437
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1421.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1421